TG Therapeutics Inc. (NASDAQ:TGTX)’s share price rose 2.2% during mid-day trading on Wednesday . The company traded as high as $6.15 and last traded at $6.14, with a volume of 86,651 shares. The stock had previously closed at $6.01.

TGTX has been the subject of a number of research reports. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a report on Monday, June 13th. Brean Capital reiterated a “buy” rating on shares of TG Therapeutics in a report on Monday, June 13th. Roth Capital reiterated a “buy” rating and set a $33.00 target price on shares of TG Therapeutics in a report on Thursday, June 9th. SunTrust Banks Inc. initiated coverage on TG Therapeutics in a report on Friday, May 27th. They set a “buy” rating and a $18.00 target price for the company. Finally, Zacks Investment Research cut TG Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 14th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. TG Therapeutics has a consensus rating of “Buy” and an average target price of $22.75.

The company has a 50-day moving average price of $5.95 and a 200-day moving average price of $7.77. The firm’s market capitalization is $331.09 million.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.04. On average, equities analysts forecast that TG Therapeutics Inc. will post ($1.23) EPS for the current fiscal year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund boosted its position in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned 0.43% of TG Therapeutics worth $2,671,000 as of its most recent filing with the SEC.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.